CTKB Cytek Biosciences Inc
Price (delayed)
$3.77
Market cap
$482.93M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.05
Enterprise value
$392.78M
Highlights
The net income has soared by 50% year-on-year and by 41% since the previous quarter
The debt has contracted by 23% YoY and by 4.3% from the previous quarter
Cytek Biosciences's EPS has plunged by 100% from the previous quarter but it has increased by 44% YoY
The quick ratio has contracted by 12% YoY and by 4.9% from the previous quarter
The gross margin has contracted by 2.3% YoY
Key stats
What are the main financial stats of CTKB
Market
Valuations
Earnings
Shares outstanding
128.1M
Market cap
$482.93M
Enterprise value
$392.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.23
Price to sales (P/S)
2.46
EV/EBIT
N/A
EV/EBITDA
39.16
EV/Sales
1.96
Revenue
$200.45M
Gross profit
$111.11M
Operating income
-$20.52M
Net income
-$6.02M
EBIT
-$461,000
EBITDA
$10.03M
Free cash flow
$21.94M
Per share
Balance sheet
Liquidity
EPS
-$0.05
EPS diluted
-$0.05
Free cash flow per share
$0.17
Book value per share
$3.07
Revenue per share
$1.53
TBVPS
$3.54
Total assets
$499.5M
Total liabilities
$103.76M
Debt
$8.6M
Equity
$395.74M
Working capital
$328.78M
Debt to equity
0.02
Current ratio
5.86
Quick ratio
5
Net debt/EBITDA
-8.99
Margins
Efficiency
Dividend
EBITDA margin
5%
Gross margin
55.4%
Net margin
-3%
Operating margin
-10.2%
Return on assets
-1.2%
Return on equity
-1.5%
Return on invested capital
-0.2%
Return on capital employed
-0.1%
Return on sales
-0.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTKB stock price
How has the Cytek Biosciences stock price performed over time
Intraday
-1.31%
1 week
3.29%
1 month
-8.05%
1 year
-33.04%
YTD
-41.91%
QTD
-5.99%
Financial performance
How have Cytek Biosciences's revenue and profit performed over time
Revenue
$200.45M
Gross profit
$111.11M
Operating income
-$20.52M
Net income
-$6.02M
Gross margin
55.4%
Net margin
-3%
The net margin has soared by 52% YoY and by 40% from the previous quarter
The net income has soared by 50% year-on-year and by 41% since the previous quarter
The operating margin has grown by 29% YoY and by 14% from the previous quarter
CTKB's operating income is up by 26% YoY and by 13% from the previous quarter
Growth
What is Cytek Biosciences's growth rate over time
Valuation
What is Cytek Biosciences stock price valuation
P/E
N/A
P/B
1.23
P/S
2.46
EV/EBIT
N/A
EV/EBITDA
39.16
EV/Sales
1.96
Cytek Biosciences's EPS has plunged by 100% from the previous quarter but it has increased by 44% YoY
CTKB's price to book (P/B) is 39% lower than its last 4 quarters average of 2.0
Cytek Biosciences's equity has increased by 2.7% from the previous quarter
The P/S is 39% below the last 4 quarters average of 4.0
The company's revenue rose by 3.9% YoY
Efficiency
How efficient is Cytek Biosciences business performance
Cytek Biosciences's ROS has soared by 98% YoY and by 97% from the previous quarter
The return on invested capital has surged by 97% since the previous quarter and by 97% year-on-year
Cytek Biosciences's return on assets has surged by 50% YoY and by 43% QoQ
Cytek Biosciences's return on equity has increased by 48% YoY and by 42% QoQ
Dividends
What is CTKB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTKB.
Financial health
How did Cytek Biosciences financials performed over time
CTKB's current ratio is down by 16% year-on-year and by 6% since the previous quarter
The quick ratio has contracted by 12% YoY and by 4.9% from the previous quarter
The debt is 98% less than the equity
The debt to equity has contracted by 33% YoY
The debt has contracted by 23% YoY and by 4.3% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.